Various types of investment companies and industrial capital are in the midst of current startups in the field of precision medical applications, such as liquid biopsy, gene editing, gene big data, and immune cell therapy. What is the significance of precision medicine ? What are the specific innovations of genetic technology in the clinic? In the primary market, what are some investment opportunities worthy of attention? What are the risks in the current genetic testing industry? Capital has placed accurate medical care At the end of January 2015, US President Barack Obama announced the US Precision Medicine Program in his 2015 State of the Union address speech, with the aim of giving everyone healthy and personalized information. Subsequently, the Chinese Ministry of Science and Technology also held the first national precision in March 2015. Medical strategy expert meeting, and plans to invest 60 billion yuan to accelerate the development of China's precision medical industry by 2030. In recent years, with the attention of governments in precision medicine, the breakthrough in clinical application, the significant reduction in sequencing costs, the maturity of cloud services and big data technology, the technology of genetic technology has been pushed to the forefront, capital Then swarmed in. Recently, Seven Bridges, a well-known biomedical data analysis company in the United States, received $45 million in Series A financing. On April 4, 2016, Human Longevity Inc., a startup in the field of genomics based in San Diego, USA, announced the completion of Series B financing on April 4, 2016, totaling US$220 million. The investors include Illumina, Celgene and others. enterprise. Domestically, Carbon Cloud Intelligence, co-founded by former Huada Gene CEO Wang Jun, has recently announced the completion of the first round of financing of nearly 1 billion yuan, led by Internet industry giant Tencent and stem cell industry leader Zhongyuan Association. At the same time, various investment companies and industrial capital are in the midst of the current hot areas of startups, such as liquid biopsy, gene editing, gene big data, and immune cell therapy, the industry's popularity is evident. What innovations has genetic technology brought to the clinic? What is the significance of precision medicine? What are the specific innovations of genetic technology in the clinic? Below, I will take a look at the leopard by introducing the application of genetic technology in the field of lung cancer. Lung cancer is the most common type of cancer in China. In China, lung cancer will kill about 600,000 people every year. It is estimated that by 2025, China's lung cancer patients will reach 1 million cases. This is a very scary data. How to prevent lung cancer through genetic technology? Suppose there is a Mr. A, 45 years old, who smokes all the year round, or long-term exposure to an environment where PM2.5 is seriously exceeded. Mr. A is a high-risk group of lung cancer and should be regularly screened for early lung cancer. At present, the clinical screening for lung cancer early screening, mainly using low-dose spiral CT and detection of blood tumor markers, but this type of screening method has a very high rate of missed detection, which will seriously delay the patient's treatment timing. In fact, at present, more than 70% of lung cancer patients in China are diagnosed with advanced lung cancer. Can genetic technology solve this problem? The answer is yes. At present, this kind of technology is developing at a high speed and is in the stage of market cultivation. It is listed as one of the top ten breakthrough technologies in 2015 by MIT Technology Review Magazine. On January 11, 2016, CFDA approved the detection product for lung cancer CTC independently developed by domestic company Geno Bio, which reduced the rate of early lung cancer detection by more than 90% of traditional methods to 20%, that is, currently Clinically, there has been a more accurate method for early lung cancer screening, but the price is still relatively expensive, and the public information shows 3000-3600 yuan per case. Next, Mr. A is taken as an example to introduce the application of genetic technology in the field of medication guidance (associated diagnosis). If Mr. A does not regularly perform lung cancer screening, but unfortunately diagnosed advanced lung cancer, surgery is often not applicable at this stage. Usually, doctors will treat Mr. A by a combination of radiotherapy and chemotherapy. How to choose chemotherapy drugs? The study found that targeted drugs are better than traditional chemotherapy, but only those with specific molecular genetic markers can benefit from it. For example, most patients with positive EGFR (epidermal growth factor receptor) mutations in lung cancer patients use targeting. The efficacy of the drug is good. At present, doctors usually need to use lung puncture. First, the patient's lung tumor tissue is collected, and then pathological and genetic testing is performed. The detection of this invasive test is of great risk to the patient, such as occurs. Pneumothorax and other symptoms. On June 1, 2016, the US FDA approved a liquid biopsy product for detecting EGFR gene mutations in patients with non-small cell lung cancer. It does not require puncture and only requires blood test. Once this product is clinically promoted, it is very suitable for patients with lung cancer who are not suitable for sampling by pulmonary puncture.
Sweeteners refer to Food Additives that can impart sweetness to soft drinks. Sweeteners can be divided into nutritive sweeteners and non-nutritive sweeteners according to their nutritional value; according to their sweetness, they can be divided into low-sweetness sweeteners and high-sweetness sweeteners; according to their source Divided into natural sweeteners and synthetic sweeteners.
Here you can find the related products in Sweeteners, we are
professional manufacturer of Sweeteners. We focused on international
export product development, production and sales. We have improved
quality control processes of Sweeteners to ensure each export qualified
product.
Here you can find the related products in Sweeteners, we are professional manufacturer of Sweeteners like D-Mannose, Raffinose, Sucralose, Maltitol, Erythritol, Sorbitol and so on.
D-Mannose, Raffinose, Sucralose, Maltitol, Erythritol, Sorbitol Xi'an Gawen Biotechnology Co., Ltd , https://www.ahualyn-bios.com